US OptionsDetailed Quotes
WVE250117P10000
- 0.10
- -0.03-23.08%
15min DelayClose Dec 30 16:00 ET
0.10High0.10Low
0.10Open0.13Pre Close3 Volume211 Open Interest10.00Strike Price30.00Turnover79.02%IV20.23%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier18DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type-0.0917Delta0.0756Gamma124.10Leverage Ratio-0.0098Theta-0.0006Rho-11.38Eff Leverage0.0045Vega
Wave Life Sciences Stock Discussion
Sign in to post a comment
$Wave Life Sciences (WVE.US)$ news coming out anytime this week 18th/19th/20th dec ...buyout? partnership?
1
$Wave Life Sciences (WVE.US)$ already have terrible earnings 😎
$Wave Life Sciences (WVE.US)$ now they file mixed shelf offering great make it take a dive more stupid 😎
$Wave Life Sciences (WVE.US)$ darn estimate EPS-28 actual EPS-47 terrible bad earnings 😎
$Lightbridge (LTBR.US)$ $Biodexa Pharmaceuticals (BDRX.US)$ $Fangdd Network (DUO.US)$ $Connexa Sports Technologies (YYAI.US)$ $Arqit Quantum (ARQQ.US)$ $SAIHEAT (SAIH.US)$ $Wave Life Sciences (WVE.US)$ $ProQR Therapeutics (PRQR.US)$ $Carmell (CTCX.US)$ $Korro Bio (KRRO.US)$ $Quoin Pharmaceuticals (QNRX.US)$ $Versus Systems (VS.US)$ $Santech Holdings (STEC.US)$ $180 Life Sciences (ATNF.US)$
1
1
$Wave Life Sciences (WVE.US)$
Wave Life Sciences Announces First-Ever Therapeutic Rna Editing in Humans Achieved in Restoraation-2 Trial of Wve-006 in Alpha-1 Antitrypsin Deficiency
Wave Life Sciences Announces First-Ever Therapeutic Rna Editing in Humans Achieved in Restoraation-2 Trial of Wve-006 in Alpha-1 Antitrypsin Deficiency
1
$Wave Life Sciences (WVE.US)$
Wave Life Sciences Ltd: Expects to Share Multidose Data From Restoraation-2 Trial in 2025
Wave Life Sciences Ltd: Expects to Share Multidose Data From Restoraation-2 Trial in 2025
1
$Wave Life Sciences (WVE.US)$ GSK plc acquires $22.3 million worth of Wave Life Sciences shares
In a notable transaction, GSK (LON:GSK) plc, a major player in the pharmaceutical industry, has recently increased its stake in Wave Life Sciences Ltd . (NASDAQ:WVE). The acquisition involved the purchase of 2,791,930 ordinary shares at a price of $8.00 per share, amounting to a total investment of $22.3 million.
This strategic move by GSK plc, which is known for its diverse portfolio of healthca...
In a notable transaction, GSK (LON:GSK) plc, a major player in the pharmaceutical industry, has recently increased its stake in Wave Life Sciences Ltd . (NASDAQ:WVE). The acquisition involved the purchase of 2,791,930 ordinary shares at a price of $8.00 per share, amounting to a total investment of $22.3 million.
This strategic move by GSK plc, which is known for its diverse portfolio of healthca...
2
No comment yet
Allan Wu : Listen to you.![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")